2018年8月全球批准新药概况

参考文献

1. 药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PN15410.html(accessed August 2018).

2. Gertz, M.A., Hereditary ATTR amyloidosis:burden of illness and diagnostic challenges. Am J Manag Care, 2017. 23(7Suppl): p. S107-s112.

3. Drugbank. https://www.drugbank.ca/drugs/DB14582 (accessedAugust 2018)

4. FDA Database. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf (accessedAugust 2018).

5. 药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PC901.html(accessed August 2018).

6. Population Council官网: https://www.popcouncil.org/news/fda-approves-the-first-one-year-contraceptive-fully-under-a-womans-control (accessed August 2018)

7. Drugbank https://www.drugbank.ca/drugs/DB14583 (accessedAugust 2018).

8. FDA Database. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf (accessed August 2018).

9. 药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PB0286.html (accessed August 2018).

10.Shire官网:https://www.shire.com/en/newsroom/2018/august/4fhgmy (accessed August 2018)

11.Gower, R.G., et al., Currentoptions for prophylactic treatment of hereditary angioedema in the UnitedStates: patient-based considerations. Allergy Asthma Proc, 2012. 33(3): p.235-40.

12.FDA Database. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761090s000lbl.pdf (accessed August 2018).

13.药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PN0863.html(accessed August 2018).

14.Tetraphase 官网:https://ir.tphase.com/news-releases/news-release-details/tetraphase-pharmaceuticals-announces-fda-approval-xeravatm (accessed August 2018).

15.Solomkin, J., et al.,Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominalInfections in an Era of Multidrug Resistance: Results From a Randomized,Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis, 2015. 60(10): p.1462-71.

16.FDA Database. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf (accessed August 2018)

17.药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PB0191.html(accessed August 2018)

18.拜耳官网:http://pharma.bayer.com/en/treatment-care/heart-and-blood-disorders/hemophilia/ (accessedAugust 2018).

19.FDA Database. https://www.fda.gov/downloads/BiologicsBloodVaccines/UCM618979.pdf (accessedAugust 2018).

20.Reding, M.T., et al., Safety andefficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost,2017. 15(3): p. 411-419.

21.药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PN0872.html (accessed August 2018).

22.WHO官网:http://www.who.int/news-room/facts-in-pictures/detail/hiv-aids (accessed August 2018).

23.FDA Database. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf (accessed August 2018).

24.FDA Database. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210807s000lbl.pdf (accessedAugust 2018)

25.药渡数据:https://data.pharmacodia.com/web/basic/basic_detail_PN2476.html(accessed August 2018).

26.咸达数据 : http://www.xanda.cn/blog/?p=10167 (accessed July 2018).

27.江苏恒瑞官网:http://www.hrs.com.cn/main_newshow/show-6018.html (accessed August 2018)

28.雪球:https://xueqiu.com/S/SH600276/112284539 (accessed July 2018)

29.WHO官网:http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/ (accessed August 2018).

30.Krishnamurti, U. and J.F.Silverman, HER2 in breast cancer: a review and update. Adv Anat Pathol, 2014.21(2): p. 100-7.

31.杨昌永,曹国庆,唐蜜,孙星,孙扬飞,张连山, 一种EGFR/HER2受体酪氨酸激酶抑制剂在制备治疗癌症的药物中的用途.201710588783 .3. 2017.

32.B Xu, F.M., Q Ouyang, W Li, ZJiang, Z Tong, Y Liu, H Li, S Yu, J Feng, S Wang, X Hu, X Zhu and J Zou, Arandomized phase II trial of pyrotinib plus capecitabine versus lapatinib pluscapecitabine in patients with HER2-positive metastatic breast cancer previouslytreated with taxanes, anthracyclines and/or trastuzumab, in 2017 San AntonioBreast Cancer Symposium., in 2017 San Antonio Breast Cancer Symposium. 2018.02.

本文为广东医谷原创文章,转载请注明来源和作者。

  • 发表于:
  • 原文链接https://kuaibao.qq.com/s/20180919A1OM5H00?refer=cp_1026
  • 腾讯「云+社区」是腾讯内容开放平台帐号(企鹅号)传播渠道之一,根据《腾讯内容开放平台服务协议》转载发布内容。
  • 如有侵权,请联系 yunjia_community@tencent.com 删除。

扫码关注云+社区

领取腾讯云代金券